Skip to content

Comparison of a Speech-Language Assessment Tool for Pragmatic and Discourse Skills in Schizophrenia Spectrum Disorders

Comparison of a Speech-Language Pathology Assessment Tool for Pragmatic and Discourse Skills for Patients With Schizophrenic Spectrum Disorders and Other Psychotic Disorders

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05742893
Acronym
VEOS
Enrollment
30
Registered
2023-02-24
Start date
2023-03-06
Completion date
2024-02-13
Last updated
2024-04-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psychotic Disorders

Brief summary

The scientific literature has largely objectified language disorders in schizophrenia. And more precisely, the impairment of pragmatic and discursive language skills. Currently, there is no standardized language assessment tool specific to these patients. The aim of this study is to compare the effectiveness of a newly developed speech-language assessment tool for pragmatic and discourse skills for patients suffering from schizophrenia .

Detailed description

The scientific literature has largely objectified language disorders in schizophrenia. And more precisely, the impairment of pragmatic and discursive language skills. Currently, there is no standardized language assessment tool specific to these patients. The aim of this study is to compare the effectiveness of a newly developed speech-language assessment tool for pragmatic and discourse skills for patients suffering from schizophrenia. To do so, patients will have to pass six tests: three tests of the new tool and three corresponding gold standard tests. The first two tests will assess pragmatic skills by means of a semi-directed interview. The next two tests will assess discourse skills through two image description tasks. Finally, the last two tests will evaluate narrative skills through the oral restitution of two heard texts. The main objective is to compare the performance of schizophrenic patients detected in the pathological zone with the scales of the new tool versus the gold standard scales. The secondary objective is to determine which skills are most affected by comparing patients' scores in pragmatic skills versus those in discourse skills. This tool would allow to precisely objectify language disorders and to optimize the multidisciplinary diagnosis and care of patients suffering from schizophrenia.

Interventions

DIAGNOSTIC_TESTMeasurement of pragmatic and discourse test scores in the two scales.

The aim of this study is to compare the effectiveness of a newly developed speech-language assessment tool for pragmatic and discourse skills for patients suffering from schizophrenia .

Sponsors

Centre Hospitalier Universitaire de Nice
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
No

Inclusion criteria

* Male or female between the ages of 18 and 60 * Patient with a diagnosis of schizophrenic spectrum disorder and other psychotic disorders meeting DSM V criteria * Patient who has been clinically and treatment stable for at least three months * Patient who can read and write French * Patient who is a beneficiary of a social security plan or similar * Patient with ability to sign free and informed consent

Exclusion criteria

* \- Patient hospitalized under restraint * Patient under guardianship * Patient who has stopped taking his or her treatment * Patient who had a change in treatment in the period of less than three months prior to the pass * Patient with a worsening of the disease in the three months prior to the inclusion visit

Design outcomes

Primary

MeasureTime frameDescription
assess of pragmatic skillsday 0The patients is evaluated by means of a semi-directed interview
assess discourse skillsday 0he patient is evaluated through two image description tasks
assess narrative skillsday 0the patients is evaluated through the oral restitution of two heard texts.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026